Atlas Trials

Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants

Clinical trial NCT04271488 · RECRUITING

Trial details

NCT number
NCT04271488
Sponsor
Eisai Co., Ltd.
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Hepatic Impairment
Start date
2020-02-27
Primary completion
2026-11-30
Enrollment
18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.